In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *
94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir ...
Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas
Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...
Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...
Grant funding awarded to support lupus-focused community programs across the United States
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...
Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...
New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track...
